HomeNewsPress ReleaseAndreia de Melo Cabral appointed Chief People...

Andreia de Melo Cabral appointed Chief People Officer.

  • Published 02/03/2022
  • Categories Press Release
  • Download Download

2nd March 2022. Bionical Emas, a global Clinical Research Organisation (CRO) providing services to the pharmaceutical and biotech sectors, has appointed Andreia de Melo Cabral as its first Chief People Officer (CPO).

Andreia joins from TFS Health Science, a global CRO, where she was the EVP HR, Talent Acquisition and Marketing & Communications.

During her time with TFS, she successfully implemented Diversity, Equity, and Inclusion initiatives that led TFS to have one of the most diverse senior leadership teams in Sweden. Andreia was also heavily involved in the rapid business scale-up which saw 400 employees hired in 12 months as well as the integration of acquisitions into the TFS Group.

Andreia has a wide range of international experience, having held senior HR management positions in publicly listed and private equity owned companies, operating in the EU, Africa, Middle East, and the US.

Andreia will be leading the Bionical Emas People Strategy across the global business, reporting to CEO, Jonathan Waring-Hughes. She joins the Executive Leadership Team. Her primary goal will be to help shape and implement the Company’s values and an integrated company culture across the business in order to support its long-term sustainable growth and operational excellence.

Jonathan Waring-Hughes, Chief Executive Officer at Bionical Emas, said:

With her considerable international and sector expertise and experience, Andreia has an important role as she focusses on several key global initiatives to support the next phase of our exciting development.

Andreia’s appointment is the first of a number of senior appointments we will be making over the next few months as we strengthen the depth and experience of our senior team to support our ambitious international growth plans.

Contact details

Bionical Emas Ltd
Katie Clayton, Head of Marketing
+44 (0) 1462 416435

Meare Consulting
Adrian Duffield
+44 (0) 7990 858548

Note to Editors

Bionical Emas is a Clinical Research Organisation (CRO) which combines Clinical Development, Early Access Program (EAP) and Clinical Trial Supply (CTS) services to deliver a unique, seamless approach to pioneering the way life-changing medicines are developed and accessed for patients around the world.

The Group deliver full clinical development services to global pharma and biotech companies. It’s integrated suite of services enables Bionical Emas to maximize access, collect data and generate evidence at every point along the drug development pathway.

Bionical Emas runs global programs, employs 200 people, and has offices in US, Europe, and Australia. It serves 10 of the top 25 pharma companies.

How can we support you?

Our dedicated teams of experts are on hand to help should you require any additional resource or further information about our services.

COVID-19 Guidance & Measures

A statement from the Bionical Emas Group on guidance & measures regarding COVID-19 - read here

In relation to staff and visitor safety, we have full risk assessments in place for all of our workplaces. These risk assessments are revisited and updated regularly, to reflect changing risks, knowledge and circumstances, and to reflect evolving Government guidance. We have not placed the risk assessments here on the website as they would become out of date too quickly. However, you are welcome to email info@bionical-emas.com to request access to our most up to date risk assessments applicable to your needs. Please note that all our staff are notified of all applicable risk assessments and updates, along with ‘quick guides’ automatically via our e-learning system.